Table 1.

Characteristics and presentation of patients with dialysis-dependent ESKD and COVID-19 admitted to a single center in New York City by vital status

Characteristicn (Column %) or Median (IQR)P Value
AllStill LivingDeceased
n5941 (69%)18 (31%)
Demographics on admission
 Age, yr63 (56–78)62 (54–73)75 (61–81)0.04
 Men33 (56)23 (56)10 (56)0.99
 Race
  White11 (19)7 (17)4 (22)0.86
  Black15 (25)11 (27)4 (22)
  Other/no answer33 (56)23 (56) 10 (56)
 Hispanic ethnicity44 (75)31 (76) 13 (72)0.76
 Charlson comorbidity index7 (5–8)7 (5–8)8 (6–10)0.03
 Body mass index, kg/m2, n=5725.2 (22.5–29.5)25 (22.5–30.3)27.7 (21.8–29.2)0.74
 Body mass index ≥25 kg/m2, n=5731 (54)21/41 (51)10/16 (63)0.56
 Hypertension58 (98)41 (100)17 (94)0.31
 Diabetes mellitus41 (69)29 (71)12 (67)0.77
 Coronary artery disease27 (46)17 (41)10 (56)0.40
 Pulmonary disease10 (17)8 (20)2 (11)0.71
 Smoker
  Current2 (3)2 (5)0 (0)0.20
  Former17 (29)9 (22)8 (44)
 Prior kidney transplant5 (8)4 (10)1 (6)0.99
 ACEi or ARB use13 (22)10 (24)3 (17)0.74
 Statin use43 (73)29 (71)14 (78)0.75
 Dialysis access
  AVF/AVG47 (80)32 (78)15 (83)0.63
  Dialysis catheter10 (17) 7 (17) 3 (17)
  Peritoneal dialysis2 (3) 2 (5)0 (0)
COVID-19 presentation
 Symptom onset to admission, d, n=48a3 (2–5)3 (2–4)3 (2–6)0.38
 Admitted after extended dialysis break, n=57b9/57 (16)7 (18)2 (11)0.70
 Presenting symptoms
  Fever29 (49)20 (49)9 (50)0.58
  Cough23 (39)17 (41)6 (33)0.39
  Dyspnea (exertional or rest)21 (36)14 (34)7 (39)0.77
  Fatigue/malaise13 (22)9 (22)4 (22)0.99
  Gastrointestinal9 (15)6 (15)3 (17)0.99
  Chills6 (10)5 (12)1 (6)0.40
  Myalgia4 (7)3 (7)1 (6)0.64
  Altered mentation5 (8)5 (12)0 (0)0.31
  None of the above symptoms3 (5)1 (2)2 (11)0.22
 Predominant initial CXR findings
  Multifocal/bilateral opacities35 (59)26 (63)9 (50)0.18
  No acute findings11 (19)8 (20)3 (17)
  Unilateral opacity6 (10)3 (7)3 (17)
  Pleural effusion4 (7)1 (2)3 (17)
  Pulmonary edema3 (5)3 (7)0 (0)
  • Pulmonary disease includes asthma (n=4), chronic obstructive pulmonary disease (n=2), idiopathic pulmonary fibrosis (n=1), lung cancer (n=2), and unspecified restrictive lung disease (n=1). Patients were considered to have been admitted after an extended (i.e., 2-day) dialysis break if they received outpatient dialysis Monday/Wednesday/Friday and were admitted on a Sunday or if they received outpatient dialysis Tuesday/Thursday/Saturday and were admitted on a Monday. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AVF, arteriovenous fistula; AVG, arteriovenous graft; CXR, chest X-ray.

  • a Nine patient records were missing these data or patient was unsure.

  • b Two patients on peritoneal dialysis were not included.